Related Experiment Video
Updated: Oct 15, 2025

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing
Published on: March 15, 2019
Micro-Heterogeneity of Antibody Molecules
Yusuke Mimura1, Radka Saldova2,3, Yuka Mimura-Kimura4
1Department of Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan. mimura.yusuke.qy@mail.hosp.go.jp.
Therapeutic monoclonal antibodies (mAbs) require comprehensive characterization of post-translational modifications (PTMs) to ensure consistent efficacy and safety. Understanding PTMs is crucial for maintaining critical quality attributes throughout a drug
Area of Science:
- Biopharmaceutical development
- Protein chemistry
- Immunology
Background:
- Therapeutic monoclonal antibodies (mAbs) are vital IgG biopharmaceuticals.
- mAbs undergo post-translational modifications (PTMs) leading to heterogeneity.
- Recombinant mAb production can alter structural fidelity and biological activity.
Purpose of the Study:
- To review common PTMs in mAbs and endogenous IgG.
- To explore the relationship between mAb structural variants and clinical performance.
- To emphasize the importance of PTM characterization for regulatory approval and drug product consistency.
Main Methods:
- Review of current literature on mAb PTMs.
- Analysis of orthogonal analytical technologies for mAb characterization.
- Discussion of quality by design principles for PTM control.
Main Results:
- PTMs, especially glycosylation at Asn297, are critical quality attributes (CQAs) impacting mAb efficacy and safety.
- Mammalian cell-produced mAbs exhibit less heterogeneity than serum-derived IgG.
- Maintaining a consistent PTM profile is essential for drug product lifespan.
Conclusions:
- Comprehensive structural characterization of mAbs, including PTMs, is mandated by regulatory authorities.
- Control of PTMs is key to ensuring the stability, activity, and immunogenicity profile of therapeutic mAbs.
- Understanding PTM-clinical performance relationships is vital for successful biopharmaceutical development.
More Related Videos
Related Concept Videos
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Affinity and Avidity
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

